Mohamed Abou-el-Enein Appointed Editor of Molecular Therapy Methods and Clinical Development

We are excited to announce that Mohamed Abou-el-Enein, MD, PhD, MSPH​​, has been appointed to a five-year term as editor-in-chief of Molecular Therapy Methods & Clinical Development (MTMCD) and began the role this month.  

Dr. Abou-el-Enein has served as MTMCD's associate editor-in-chief for the past two years, which will allow him to make a smooth transition in leadership. His vision for MTMCD is one of consistent innovation, evolution, and growth. Dr. Abou-el-Enein firmly believes that MTMCD has the potential to become a leading voice in the gene and cell therapy landscape. He is eager to leverage his experience and expertise to expand the journal’s reach and impact. 

Dr. Abou-el-Enein is associate professor of clinical medicine (oncology), pediatrics, and stem cell biology and regenerative medicine at USC Keck School of Medicine as well as executive director of USC/CHLA cell therapy program. He is an internationally recognized expert in planning and executing clinical development programs, designing and operating academic GMP facilities, and translating cell and gene therapy products from preclinical research to clinical applications. His research laboratory is dedicated to pioneering advancements in CAR T-cell therapies, including optimizing engineering techniques and devising novel strategies for allogeneic applications and genetic delivery tools to increase both accessibility and scalability.

Related Articles